Lignocaine Injection

SECTION 2: Hazards identification

Appearance: Clear, colorless solution

Hazard statements

Non-hazardous in accordance with international standards for workplace safety.

Additional information

Short Term: Harmful if swallowed . May cause mild eye irritation. May cause slight skin irritation. (based on components) . Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure. Known Clinical Effects: Adverse effects associated with therapeutic use include dizziness, nervousness, agitation, drowsiness, apprehension, euphoria, blurred/double vision, slurred speech, tremors, convulsions, and seizure. Respiratory depression and arrest may follow. Other, more serious effects seen with IV use of this drug, particularly when it is administered rapidly, are cardiovascular collapse, central nervous system depression, and/or hypotension. EU Indication of danger: Not classified Australian Hazard Classification

Hazardous Ingredients

Non-Dangerous Goods (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.